KRAS mutation (any)

Activating KRAS mutations (codons 12, 13, 61 and others) detected by sequencing or PCR; used as a predictive marker, including as a negative predictor of response to anti-EGFR antibodies in colorectal cancer.

CI-BIO-00000016KRAS graph →NCIt C41361 Tumor-agnostic · 4 approval rows

Also calledKRAS-mutant · KRAS-mutated · RAS mutation

Tissue-agnostic indications

Approval rows flagged tumor-agnostic (4)

Dabrafenib US FDA · Mar 16, 2023 · drug in derived setRegulatory approved
Dabrafenib US FDA · May 29, 2013 · drug in derived setRegulatory approved
Trametinib US FDA · Mar 16, 2023 · drug in derived setRegulatory approved
Trametinib US FDA · May 29, 2013 · drug in derived setRegulatory approved

The flag is the source's (openFDA label text), never inferred; the full indication text of each row is in the Approvals section below.

Derived

Associated cancers (26)

Cancers mapped in ACCEPTED CIViC predictive, prognostic or diagnostic items whose variant (molecular markers) or gene (gene-level markers) is in this biomarker's scope. Counts by type and native level; each row links to the cancer's evidence tab.

Computedrule biomarker-links-v1

Cancer	Items	Predictive	Prognostic	Diagnostic	Levels A / B / C / D / E
Malignant Colorectal Neoplasm	95	89	6	—	4 / 35 / 25 / 31 / 0
Lung Non-Small Cell Carcinoma	31	25	5	1	2 / 24 / 1 / 3 / 1
Multiple Myeloma	17	13	4

Derived

Drugs with predictive evidence (57)

Therapies named in in-scope PREDICTIVE CIViC items, plus targets of PREDICTS_RESPONSE_TO knowledge edges from in-scope variants. Sensitivity and resistance are counted separately and never merged into a verdict.

Computedrule biomarker-links-v1

Drug	CIViC items	Sensitivity	Resistance	Best level	Edges (S / R)	Cancer context
CetuximabMonoclonal Antibody	47	6	41	A	5 / 39	Malignant Colorectal Neoplasm, Malignant Ovarian Neoplasm
PanitumumabMonoclonal Antibody	21	1	20	A	1 / 19	Colon Mucinous Adenocarcinoma, Malignant Colorectal Neoplasm
SelumetinibSmall Molecule	19	18	1	A	14 / 1	Lung Adenocarcinoma, Lung Non-Small Cell Carcinoma, Malignant Colorectal Neoplasm, Malignant Neoplasm
MelphalanSmall Molecule	13	—	13	B	0 / 13	Multiple Myeloma
ErlotinibSmall Molecule	11	3	8	B	1 / 7	Lung Adenocarcinoma, Lung Non-Small Cell Carcinoma, Malignant Colorectal Neoplasm, Malignant Pancreatic Neoplasm +1
Chemotherapy	10	—	10	B	0 / 9	Malignant Colorectal Neoplasm
GefitinibSmall Molecule	9	—	9	B	0 / 9	Lung Adenocarcinoma, Lung Non-Small Cell Carcinoma, Malignant Colorectal Neoplasm, Malignant Lung Neoplasm
Regorafenib AnhydrousSmall Molecule	9	1	8	B	0 / 7	Malignant Colorectal Neoplasm
DocetaxelSmall Molecule	8	7	1	A	5 / 1	Cutaneous Melanoma, Lung Non-Small Cell Carcinoma
TrametinibSmall Molecule	8	7	1	B	5 / 1	Lung Non-Small Cell Carcinoma, Malignant Colorectal Neoplasm, Malignant Neoplasm, Pancreatic Adenocarcinoma
DactolisibSmall Molecule	7	7	—	D	7 / 0	Lung Adenocarcinoma, Malignant Colorectal Neoplasm
VemurafenibSmall Molecule	5	1	4	B	0 / 4	Hairy Cell Leukemia, Malignant Colorectal Neoplasm, Melanoma
AfatinibSmall Molecule	4	4	—	C	4 / 0	Lung Non-Small Cell Carcinoma, Malignant Colorectal Neoplasm, Pancreatic Ductal Adenocarcinoma
IrinotecanSmall Molecule	4	1	3	B	1 / 2	Malignant Colorectal Neoplasm
Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor	3	2	1	B	2 / 1	Malignant Colorectal Neoplasm, Malignant Neoplasm
AbemaciclibSmall Molecule	2	2	—	B	2 / 0	Lung Non-Small Cell Carcinoma
AdagrasibSmall Molecule	2	2	—	A	2 / 0	Malignant Colorectal Neoplasm, Solid Neoplasm
BinimetinibSmall Molecule	2	2	—	B	2 / 0	Malignant Colorectal Neoplasm, Malignant Ovarian Serous Tumor
B-Raf/VEGFR-2 Inhibitor RAF265	2	2	—	D	2 / 0	Lung Non-Small Cell Carcinoma, Malignant Colorectal Neoplasm
CarboplatinSmall Molecule	2	1	1	B	1 / 1	Cutaneous Melanoma, Ovarian Carcinoma
DabrafenibSmall Molecule	2	—	2	B	0 / 2	Lung Adenocarcinoma, Melanoma
GemcitabineSmall Molecule	2	—	2	B	0 / 2	Malignant Pancreatic Neoplasm, Pancreatic Adenocarcinoma
PalbociclibSmall Molecule	2	2	—	D	2 / 0	Lung Non-Small Cell Carcinoma, Malignant Colorectal Neoplasm
SorafenibSmall Molecule	2	2	—	B	2 / 0	Cutaneous Melanoma, Hepatocellular Carcinoma
SotorasibSmall Molecule	2	2	—	A	2 / 0	Lung Non-Small Cell Carcinoma, Malignant Colorectal Neoplasm
TeprotumumabMonoclonal Antibody	2	2	—	B	2 / 0	Lung Non-Small Cell Carcinoma, Malignant Colorectal Neoplasm
BevacizumabMonoclonal Antibody	2	—	2	B	0 / 1	Malignant Colorectal Neoplasm
CrizotinibSmall Molecule	2	1	1	C	1 / 0	Malignant Colorectal Neoplasm, Malignant Neoplasm
RefametinibSmall Molecule	2	2	—	B	1 / 0	Hepatocellular Carcinoma, Malignant Colorectal Neoplasm
MEK Inhibitor RO4987655	2	1	1	B	—	Lung Non-Small Cell Carcinoma, Malignant Colorectal Neoplasm
Akt Inhibitor MK2206	1	1	—	C	1 / 0	Pancreatic Carcinoma
ARS-853	1	1	—	D	1 / 0	Malignant Neoplasm
AtezolizumabMonoclonal Antibody	1	1	—	B	1 / 0	Lung Non-Small Cell Carcinoma
AZD5438	1	1	—	D	1 / 0	Malignant Neoplasm
Cetuximab/Irinotecan Regimen	1	—	1	C	0 / 1	Malignant Colorectal Neoplasm
CisplatinSmall Molecule	1	—	1	B	0 / 1	Head and Neck Squamous Cell Carcinoma
DasatinibSmall Molecule	1	1	—	D	1 / 0	Malignant Colorectal Neoplasm
DecitabineSmall Molecule	1	1	—	D	1 / 0	Malignant Ovarian Neoplasm
DivarasibSmall Molecule	1	1	—	B	1 / 0	Lung Non-Small Cell Carcinoma
FOLFOX-4 Regimen	1	—	1	B	0 / 1	Malignant Colorectal Neoplasm
G-573	1	1	—	D	1 / 0	Malignant Neoplasm
Immune Checkpoint Inhibitor	1	1	—	E	1 / 0	Lung Non-Small Cell Carcinoma
Immunomodulatory Oligonucleotide	1	1	—	D	1 / 0	Malignant Colorectal Neoplasm
IxazomibSmall Molecule	1	—	1	D	0 / 1	Malignant Colorectal Neoplasm
MEK Inhibitor GDC-0623	1	1	—	D	1 / 0	Malignant Neoplasm
NivolumabMonoclonal Antibody	1	1	—	B	1 / 0	Lung Non-Small Cell Carcinoma
PaclitaxelSmall Molecule	1	—	1	B	0 / 1	Ovarian Carcinoma
PemetrexedSmall Molecule	1	1	—	B	1 / 0	Lung Non-Small Cell Carcinoma
PI3Kbeta Inhibitor AZD8186	1	1	—	D	1 / 0	Pancreatic Adenocarcinoma
PictilisibSmall Molecule	1	—	1	D	0 / 1	Malignant Breast Neoplasm
SCH772984Small Molecule	1	1	—	D	1 / 0	Pancreatic Adenocarcinoma
SirolimusSmall Molecule	1	1	—	D	1 / 0	Lung Adenocarcinoma
Therapeutic Tumor Infiltrating Lymphocytes	1	1	—	C	1 / 0	Malignant Colorectal Neoplasm
OxaliplatinSmall Molecule	1	—	1	B	—	Malignant Colorectal Neoplasm
RidaforolimusSmall Molecule	1	1	—	B	—	Malignant Endometrial Neoplasm
SalirasibSmall Molecule	1	1	—	B	—	Lung Adenocarcinoma
TemsirolimusSmall Molecule	1	1	—	B	—	Malignant Endometrial Neoplasm

Curatedcivic items and knowledge edges as curated at the source.

Curated evidence

Predictive evidence items (167)

ACCEPTED CIViC predictive items in scope, grouped by molecular profile and therapy with native level, direction and cancer context. 50 per page.

civicCuratedShowing 151–167 of 167 evidence items · levels, directions and significance as curated at the source; each row links to its CIViC record.

Therapy	Cancer	Type	Level	Direction · significance	Rating (1–5)	Status	Evidence	Source
KRAS G12D3
Melphalan	Multiple Myeloma	Predictive	D	Supports Resistance	—	accepted	EID2251 In in vitro experiments, myeloma cell lines expressing activating NRAS and KRAS mutations are less sensitive to the apoptosis-inducing effects of dexamethasone, doxorubicin, and melphalan in compariso… (full text at CIViC) PMID 12483530 · Rowley et al., 2002 · Open in CIViC	civic
〃	Multiple Myeloma	Predictive	D	Supports Resistance	2	accepted	EID2252 In in vitro experiments, myeloma cell lines expressing activating NRAS and KRAS mutations are less sensitive to the apoptosis-inducing effects of dexamethasone, doxorubicin, and melphalan in compariso… (full text at CIViC) PMID 16497971 · Hoang et al., 2006 · Open in CIViC	civic
Akt Inhibitor MK2206	Pancreatic Carcinoma	Predictive	C	Supports Sensitivity Response	2	accepted	EID937 Among 33 patients treated with pan-AKT inhibitor MK-2206 in this phase 1 study, one patient with pancreatic adenocarcinoma and PTEN loss and a KRAS G12D mutation experienced a decrease of approximatel… (full text at CIViC) PMID 22025163 · Yap et al., 2011 · Open in CIViC	civic
KRAS G12C4
Melphalan	Multiple Myeloma	Predictive	D	Supports Resistance	2	accepted	EID2261 In in vitro experiments, myeloma cell lines expressing activating NRAS and KRAS mutations are less sensitive to the apoptosis-inducing effects of dexamethasone, doxorubicin, and melphalan in compariso… (full text at CIViC) PMID 11050000 · Rowley et al., 2000 · Open in CIViC	civic
〃	Multiple Myeloma	Predictive	D	Supports Resistance	—	accepted	EID2262 In in vitro experiments, myeloma cell lines expressing activating NRAS and KRAS mutations are less sensitive to the apoptosis-inducing effects of dexamethasone, doxorubicin, and melphalan in compariso… (full text at CIViC) PMID 12483530 · Rowley et al., 2002 · Open in CIViC	civic
〃	Multiple Myeloma	Predictive	D	Supports Resistance	2	accepted
KRAS G12S3
Melphalan	Multiple Myeloma	Predictive	D	Supports Resistance	2	accepted	EID2277 In in vitro experiments, myeloma cell lines expressing activating NRAS and KRAS mutations are less sensitive to the apoptosis-inducing effects of dexamethasone, doxorubicin, and melphalan in compariso… (full text at CIViC) PMID 11050000 · Rowley et al., 2000 · Open in CIViC	civic
〃	Multiple Myeloma	Predictive	D	Supports Resistance	2	accepted	EID2278 In in vitro experiments, myeloma cell lines expressing activating NRAS and KRAS mutations are less sensitive to the apoptosis-inducing effects of dexamethasone, doxorubicin, and melphalan in compariso… (full text at CIViC) PMID 12483530 · Rowley et al., 2002 · Open in CIViC	civic
〃	Multiple Myeloma	Predictive	D	Supports Resistance	2	accepted
KRAS RS617643701
Carboplatin + PaclitaxelSubstitutes	Ovarian CarcinomaALIAS	Predictive	B	Supports Resistance	3	accepted	EID664 The functional variant rs61764370 in the KRAS gene 3' UTR (KRAS-variant) was found to be correlated with platinum-based chemotherapy resistance in patients with Epithelial Ovarian Cancer (EOC). 291 EO… (full text at CIViC) PMID 22139083 · Ratner et al., 2012 · Open in CIViC	civic
KRAS G12/G132
Gemcitabine + TrametinibCombination	Pancreatic Adenocarcinoma	Predictive	B	Supports Resistance	4	accepted	EID622 Adding trametinib to gemcitabine does not improve overall survival (OS), progression-free survival (PFS), overall response rate (ORR) or duration of response (DOR) in patients with untreated metastati… (full text at CIViC) PMID 24915778 · Infante et al., 2014 · Open in CIViC	civic
Trametinib	Pancreatic Adenocarcinoma	Predictive	B	Does Not Support Sensitivity Response	3	accepted	EID990 KRAS G12/G13 status was evaluated in cell-free DNA (cfDNA) of patients with untreated metastatic adenocarcinoma of the pancreas that were randomised (1:1) to receive gemcitabine plus trametinib or pla… (full text at CIViC) PMID 24915778 · Infante et al., 2014 · Open in CIViC	civic
KRAS Mutation1
PI3Kbeta Inhibitor AZD8186 + SCH772984Combination	Pancreatic Adenocarcinoma	Predictive	D	Supports Sensitivity Response	4	accepted	EID1003 Inhibition of ERK in 11 KRAS mutant pancreatic cancer cell lines with SCH772984 was more effective than MEK Inhibition. Combined Treatment with PI3K Inhibitor AZD8186 was more effective than either ag… (full text at CIViC) PMID 26725216 · Hayes et al., 2016 · Open in CIViC	civic
KRAS Exon 2 Mutation1
Erlotinib	Pancreatic Carcinoma	Predictive	B	Does Not Support Resistance	3	accepted	EID916 KRAS exon 2 was mutated in 121 of 173 (70%) patients with advanced pancreatic cancer and did not show an association with response to erlotinib treatment. PMID 23435671 · Boeck et al., 2013 · Open in CIViC	civic
NRG1 Fusion + KRAS WildtypeNRG1 KRAS1
Afatinib	Pancreatic Ductal Adenocarcinoma	Predictive	C	Supports Sensitivity Response	3	accepted	EID7492 Whole genome sequencing and transcriptomic analysis were performed on 47 advanced PDAC patients. 3/47 patients were KRAS wildtype and all three of these cases harbored a NRG1 fusion. A 59-year-old met… (full text at CIViC) PMID 31068372 · Jones et al., 2019 · Open in CIViC	civic
NRG1 Fusion + KRAS WildtypeNRG1 KRAS1
Afatinib	Pancreatic Ductal Adenocarcinoma	Predictive	C	Supports Sensitivity Response	3	accepted	EID7493 Whole genome sequencing and transcriptomic analysis were performed on 47 advanced PDAC patients. 3/47 patients were KRAS wildtype and all three of these cases harbored a NRG1 fusion. In a 54-year-old … (full text at CIViC) PMID 31068372 · Jones et al., 2019 · Open in CIViC	civic

Regulatory

Approvals mentioning the linked drugs (500)

Approval records of the derived drug set, plus records whose indication text names this biomarker. Each record names its authority, jurisdiction, indication text and status — a drug approved in one jurisdiction for one indication is not 'approved' in general, and an approval listed here is not necessarily restricted to this biomarker.

Computedrule biomarker-links-v1

openfdaRegulatory50 approval records from 3 sources (hover a row badge for its dataset) · authority, jurisdiction and indication text as published.

Drug	Jurisdiction · authority	Cancer	Indication	Status	Approval date	Source
Dabrafenib	US FDA	Tumor-agnostic	the treatment of adult and pediatric patients 1 year of age and older with unresectable or metastatic solid tumors with BRAF V600E mutation who have progressed following prior treatment and have no satisfactory alternative treatment options. This indication is approved under accelerated approval based on overall response rate (ORR) and duration of response (DoR). Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial(s). • the treatment of pediatric patients 1 year of age and older with low-grade glioma (LGG) with a BRAF V600E mutation who require systemic therapy. • TAFINLAR is not indicated for treatment of patients with wild-type BRAF solid tumors. ( 5.2 )accelerated	approved	Mar 16, 2023	openfda
Dabrafenib	US FDA	Tumor-agnostic	the treatment of adult and pediatric patients 1 year of age and older with unresectable or metastatic solid tumors with BRAF V600E mutation who have progressed following prior treatment and have no satisfactory alternative treatment options. This indication is approved under accelerated approval based on overall response rate (ORR) and duration of response (DoR). Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial(s). • the treatment of pediatric patients 1 year of age and older with low-grade glioma (LGG) with a BRAF V600E mutation who require systemic therapy. • TAFINLAR is not indicated for treatment of patients with wild-type BRAF solid tumors. ( 5.2 )accelerated	approved

Health Canada DIN rows carry no indication text and only match by drug.

Clinical trials

Active trials (1,652)

Trials with an active ClinicalTrials.gov status, an intervention mapped to a derived drug and a condition mapped to an associated cancer. 798 recruiting · 366 active phase 3 · 7,948 in any status. Most recently updated first, 50 per page.

Computedrule biomarker-links-v1

clinicaltrialsPublishedShowing 1,301–1,350 of 1,652 active studies · status and phase as posted by the registrant; each row links to the study record.

NCT	Title	Status	Phase	Enrollment (n)	Sponsor	Countries	Last update	Source
NCT03907852	Phase 1/2 Trial of Gavo-cel (TC-210) in Patients With Advanced Mesothelin-Expressing Cancer	active not recruiting	Phase 1 / Phase 2	57	TCR2 TherapeuticsINDUSTRY	2	Aug 27, 2025	clinicaltrials
NCT06887218	5-Fluorouracil/Leucovorin (5FU/LV) in Combination With Regorafenib in Patients With Metastatic Colorectal Cancer	recruiting	Phase 2	57	The Methodist Hospital Research InstituteOTHER	1	Aug 27, 2025	clinicaltrials
NCT06867822	Trial of ProAgio in Advanced/Metastatic Colorectal Cancer	recruiting	Phase 1	27	University of Alabama at BirminghamOTHER	1	Aug 24, 2025	clinicaltrials
NCT07134205	The Study of JMT101 Combined With Irinotecan as a ≥3rd-Line Treatment in Metastatic Colorectal Cancer	not yet recruiting	Phase 3	252	Shanghai JMT-Bio Inc.INDUSTRY	0	Aug 21, 2025	clinicaltrials
NCT03170960	Study of Cabozantinib Alone or in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid Tumors	active not recruiting	Phase 1	914	ExelixisINDUSTRY	9	Aug 17, 2025	clinicaltrials
NCT06758544	A Single-arm, Open-label Clinical Study to Evaluate the Efficacy and Safety of VRT106 in Combination With Chemotherapy for Resectable Pancreatic Cancer	recruiting	Phase 1 / Phase 2	18	Guangdong Provincial People's HospitalOTHER	1	Aug 17, 2025	clinicaltrials
NCT07128251	A Single-Arm, Multicenter, Exploratory Clinical Study of Transarterial Chemoembolization (TACE) Combined With Iparomlimab and Tuvonralimab Injection and Bevacizumab Injection for the Treatment of Unresectable, Non-Metastatic Hepatocellular Carcinoma (HCC)	not yet recruiting	Phase 2	47	Anhui Provincial HospitalOTHER_GOV	0	Aug 17, 2025	clinicaltrials
NCT05822752	Study to Evaluate Adverse Events, and Change in Disease Activity, When Intravenously (IV) Infused With Livmoniplimab in Combination With IV Infused Budigalimab in Adult Participants With Hepatocellular Carcinoma (HCC)(LIVIGNO-1)	active not recruiting	Phase 2	130	AbbVieINDUSTRY	7	Aug 14, 2025	clinicaltrials
NCT06323382	Locoregional Therapy Combined With Bevacizumab and PD1/L1 Inhibitor in Advanced Hepatocellular Carcinoma	recruiting	—	240	Sun Yat-sen UniversityOTHER	1	Aug 14, 2025	clinicaltrials
NCT07120451	Combination Therapy of Senaparib and Bevacizumab for First-line Maintenance Therapy in Newly Diagnosed Advanced Homologous Recombination Proficient Ovarian Cancer Based on Exosome Protein Marker	not yet recruiting	Phase 2	37	Fudan UniversityOTHER	1	Aug 13, 2025	clinicaltrials
NCT07114666	XH001 (New Antigen Tumor Vaccine) Combined With Chemotherapy as Adjuvant Therapy in Pancreatic Cancer	not yet recruiting	N/A	12	Peking Union Medical College HospitalOTHER	1	Aug 11, 2025	clinicaltrials
NCT06095141	Cisplatin to Patients With Pancreatic Cancer and Homologous Recombination Deficiency(PTCA199-6)	recruiting	Phase 2 / Phase 3	30	Fudan UniversityOTHER	1	Aug 7, 2025	clinicaltrials
NCT06896422	Randomized Trial of Glutathione With Anti-PD-1 and Chemotherapy in Advanced NSCLC	recruiting	Phase 1	80	The First Affiliated Hospital of Zhengzhou UniversityOTHER	1	Aug 7, 2025	clinicaltrials
NCT07108504	Efficacy and Safety of LM-302 Combined With Gemcitabine CLDN 18.2 Positive Unresectable Locally Advanced or Metastatic Pancreatic Cancer	not yet recruiting	Phase 2	30	Shanghai Zhongshan HospitalOTHER	0	Aug 7, 2025	clinicaltrials
NCT04778839	Study of Paclitaxel Micelles for Injection in Chinese Patients With Advanced Solid Tumors.	recruiting	Phase 1	98	First Affiliated Hospital of Zhejiang UniversityOTHER	1	Aug 6, 2025	clinicaltrials
NCT06856187	Second-line Standard Treatment Sequential TAS-102 and Bevacizumab Combined With Local Treatment in Advanced Colorectal Cancer(TASBEL)	recruiting	Phase 2	119	Fudan UniversityOTHER	1	Aug 6, 2025	clinicaltrials
NCT03493048	Cetuximab Plus FOLFOXIRI vs Cetuximab Plus FOLFOX For CRCLM	active not recruiting	Phase 2	146	Sun Yat-sen UniversityOTHER	1	Aug 3, 2025	clinicaltrials
NCT05442060	To Evaluate OBI-833/OBI-821 in Combination With First-Line Erlotinib in Patients With EGFR-Mutated, Globo H-Positive, Locally Advanced or Metastatic Non-Small Cell Lung Cancer(EGFR)	recruiting	Phase 2	60	OBI Pharma, IncINDUSTRY	1	Aug 3, 2025	clinicaltrials
NCT02304809	Phase 2 Study Assessing Secured Access to Vemurafenib for Patients With Tumors Harboring BRAF Genomic Alterations(AcSé)	active not recruiting	Phase 2	216	UNICANCEROTHER	1	Aug 1, 2025	clinicaltrials
NCT03649048	Low-Dose Weekly vs High-Dose Cisplatin(RADIO)	recruiting	N/A	100	London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph'sOTHER	1	Jul 31, 2025	clinicaltrials
NCT06441565	Fruquintinib With or Without HAI-FOLFOX for Refractory Colorectal Cancer	recruiting	Phase 2 / Phase 3	84	Sun Yat-sen UniversityOTHER	1	Jul 30, 2025	clinicaltrials
NCT07093931	Efficacy and Safety of Lobaplatin and Carboplatin as Neoadjuvant Therapy in HER-2 Positive Breast Cancer	not yet recruiting	Phase 4	468	Shandong Cancer Hospital and InstituteOTHER	1	Jul 30, 2025	clinicaltrials
NCT04341181	ProTarget - A Danish Nationwide Clinical Trial on Targeted Cancer Treatment Based on Genomic Profiling(ProTarget)	recruiting	Phase 2	300	Ulrik LassenOTHER	1	Jul 25, 2025	clinicaltrials
NCT05275777	A Phase Ib Safety lead-in, Followed by Phase II Trial of ADG106 in Combination With Neoadjuvant Chemotherapy in HER2 Negative Breast Cancer	active not recruiting	Phase 1 / Phase 2	66	National University Hospital, SingaporeOTHER	1	Jul 25, 2025	clinicaltrials
NCT06208410	A Clinical Study of JS105 in Combination With Other Anti-tumor Therapies in Patients With Solid Tumors	recruiting	Phase 1 / Phase 2	306	Risen (Suzhou) Pharma Tech Co., Ltd.INDUSTRY	1	Jul 25, 2025	clinicaltrials
NCT07083505	A Study Comparing the Efficacy and Safety of HB1801 With Taxotere® in Advanced Breast Cancer	not yet recruiting	Phase 2	60	CSPC ZhongQi Pharmaceutical Technology Co., Ltd.INDUSTRY	0	Jul 24, 2025	clinicaltrials
NCT04136535	Pemetrexed and Carboplatin With or Without Anlotinib Hydrochloride for Osimertinib-resistant Non-squamous NSCLC(PCA)	recruiting	Phase 2	105	Fudan UniversityOTHER	1	Jul 22, 2025	clinicaltrials
NCT04052880	Study of SubQ Dara With Dose-Attenuated Bortezomib, Lenalidomide, Dexamethasone in Elderly NDMM	active not recruiting	Phase 2	17	Larysa SanchezOTHER	1	Jul 20, 2025	clinicaltrials
NCT06935188	Dalpicilib Plus Cetuximab Compared With Cetuximab Alone in HPV-negative, Anti-PD-1-resistant R/M HNSCC	recruiting	Phase 2	98	Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong UniversityOTHER	1	Jul 18, 2025	clinicaltrials
NCT05755672	On-treatment Biomarkers in Metastatic Colorectal Cancer for Life(On-CALL)	recruiting	—	100	Region SkaneOTHER	1	Jul 17, 2025	clinicaltrials
NCT07071844	BETWEEN: Biweekly Bevacizumab + Trifluridine/Tipiracil to Reduce Grade 3-4 Neutropenia in mCRC Patients(BETWEEN)	not yet recruiting	Phase 2	162	GERCOR - Multidisciplinary Oncology Cooperative GroupOTHER	1	Jul 17, 2025	clinicaltrials
NCT07064668	Tauroursodeoxycholic Acid Combined With PD-1/PD-L1 Immunotherapy in Advanced Hepatocellular Carcinoma: A Prospective Study	not yet recruiting	Phase 2	300	Tongji HospitalOTHER	1	Jul 15, 2025	clinicaltrials
NCT07062263	Trastuzumab Plus Chemotherapy vs Chemotherapy Alone in First-line HER2 Positive Advanced Biliary Tract Cancer Patients(TAB-2)	recruiting	Phase 3	220	Tata Memorial CentreOTHER	1	Jul 14, 2025	clinicaltrials
NCT03725059	Study of Pembrolizumab (MK-3475) Versus Placebo in Combination With Neoadjuvant Chemotherapy & Adjuvant Endocrine Therapy in the Treatment of Early-Stage Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative (ER+/HER2-) Breast Cancer (MK-3475-756/KEYNOTE-756)	active not recruiting	Phase 3	1,240	Merck Sharp & Dohme LLCINDUSTRY	24	Jul 11, 2025	clinicaltrials
NCT06835400	Oral Paclitaxel + Encequidar vs IV Paclitaxel in Treatment of HER2 Negative Metastatic Breast Cancer	not yet recruiting	Phase 3	340	Health Hope PharmaINDUSTRY	0	Jul 11, 2025	clinicaltrials
NCT06112808	A Clinical Study of the Pharmacokinetics and Safety of BCD-263 and Opdivo® as Monotherapy in Subjects With Advanced Melanoma of the Skin	active not recruiting	Phase 1	300	BiocadINDUSTRY	2	Jul 8, 2025	clinicaltrials
NCT06640530	Clinical Study of the Efficacy and Safety of BCD-263 and Opdivo® as Monotherapy in Subjects With Advanced Melanoma of the Skin(UNIVERSE)	active not recruiting	Phase 3	392	BiocadINDUSTRY	3	Jul 8, 2025	clinicaltrials
NCT04721015	Study of Intravenous (IV) ABBV-637 Alone or in Combination With IV Docetaxel/Osimertinib to Assess Adverse Events and Change in Disease Activity in Adult Participants With Relapsed/Refractory (R/R) Solid Tumors	active not recruiting	Phase 1	81	AbbVieINDUSTRY	8	Jul 3, 2025	clinicaltrials
NCT07050043	Low Dose Nivolumab With Chemotherapy vs Standard Chemotherapy as First-Line Treatment in Advanced or Metastatic NSCLC(LEDANG)	recruiting	Phase 3	123	Dr Arvindran A/L AlagaOTHER_GOV	1	Jul 3, 2025	clinicaltrials
NCT06893887	Individualized Comprehensive Treatment for Advanced Hepatocellular Carcinoma(ICT-HCC)	recruiting	N/A	300	Nanjing Tianyinshan HospitalOTHER	1	Jul 2, 2025	clinicaltrials
NCT05310643	Nivolumab and Ipilimumab in Anti-PD1-Resistant dMMR/MSI mCRC(NIPIRESCUE)	recruiting	Phase 2	30	GERCOR - Multidisciplinary Oncology Cooperative GroupOTHER	1	Jul 1, 2025	clinicaltrials
NCT06946927	A Phase Ib Study of JMKX001899 in Combination With Other Therapies in Advanced NSCLC Harboring KRAS G12C Mutation	recruiting	Phase 1	72	JemincareINDUSTRY	1	Jul 1, 2025	clinicaltrials
NCT05116462	Neoadjuvant and Adjuvant Therapy Studies of Sindilizumab in Resectable Lung Cancer	active not recruiting	Phase 3	506	Innovent Biologics (Suzhou) Co. Ltd.INDUSTRY	1	Jun 26, 2025	clinicaltrials
NCT05451043	Durvalumab and Tremelimumab in Combination With Propranolol and Chemotherapy for Treatment of Advanced Hepatopancreabiliary Tumors (BLOCKED)	recruiting	Phase 2	62	AHS Cancer Control AlbertaOTHER	1	Jun 26, 2025	clinicaltrials
NCT07035392	Adebrelimab + Chemotherapy as Neoadjuvant Therapy for Resectable NSCLC	not yet recruiting	Phase 2	32	Zhangzhou Municipal HospitalOTHER	0	Jun 25, 2025	clinicaltrials
NCT03522246	A Study in Ovarian Cancer Patients Evaluating Rucaparib and Nivolumab as Maintenance Treatment Following Response to Front-Line Platinum-Based Chemotherapy(ATHENA)	active not recruiting	Phase 3	1,097	pharmaand GmbHINDUSTRY	24	Jun 24, 2025	clinicaltrials
NCT06885385	A Phase 2 Study Evaluating the Safety and Efficacy of JS207 With or Without JS015 in Combination With Chemotherapy in Patients With Colorectal Cancer	recruiting	Phase 2	60	Shanghai Junshi Bioscience Co., Ltd.OTHER	1	Jun 24, 2025	clinicaltrials
NCT06954584	Fluzoparib+Bevacizumab/Dietary Intervention vs Fluzoparib Monotherapy as First-line Maintenance in HRD+/- Advanced Ovarian Cancer	recruiting	Phase 3	424	Tongji HospitalOTHER	1	Jun 24, 2025	clinicaltrials
NCT03341936	Neodjuvant Nivolumab and Lirilumab, Followed by Surgery, Followed by Adjuvant Nivolumab and Lirilumab, in SCCHN	active not recruiting	Phase 2	29	Dana-Farber Cancer InstituteOTHER	1	Jun 18, 2025	clinicaltrials
NCT04024878	NeoVax With Nivolumab in Patients With Ovarian Cancer	active not recruiting	Phase 1	22	Dana-Farber Cancer InstituteOTHER	1	Jun 18, 2025	clinicaltrials

A study listed here tests a linked drug in a linked cancer; it does not necessarily select participants on this biomarker.

Approval rows flagged tumor-agnostic (4)

Associated cancers (26)

Drugs with predictive evidence (57)

Predictive evidence items (167)

Approvals mentioning the linked drugs (500)

Active trials (1,652)

Linked publications (113)